Repare Therapeutics Inc Cash Flow Conversion Efficiency
Repare Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.65 Million) by net assets ($115.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Repare Therapeutics Inc (2018–2024)
Cash flow conversion efficiency of Repare Therapeutics Inc from 2018 to 2024. This chart illustrates how Repare Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Repare Therapeutics Inc for real-time trading data and today's change.
Repare Therapeutics Inc Cash Flow Conversion Ratio Explained
Repare Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Repare Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repare Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Repare Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynagas LNG Partners LP
NYSE:DLNG
|
0.054x |
|
Phu Tai JSC
VN:PTB
|
0.161x |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
0.023x |
|
Changsha Kaiyuan Instruments
SHE:300338
|
2.512x |
|
Banco Hipotecario SA
BA:BHIP
|
-0.246x |
|
Cheffelo AB
ST:CHEF
|
0.097x |
|
Chernan Metal Industrial
TWO:3631
|
0.004x |
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
0.040x |
Annual Cash Flow Conversion Efficiency for Repare Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Repare Therapeutics Inc from 2018 to 2024. Review cash generation quality of Repare Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $151.13 Million | $-76.44 Million | -0.506x | +15.64% |
| 2023-12-31 | $212.08 Million | $-127.16 Million | -0.600x | -52146.58% |
| 2022-12-31 | $279.52 Million | $322.00K | 0.001x | +100.39% |
| 2021-12-31 | $288.42 Million | $-85.80 Million | -0.297x | -1302.41% |
| 2020-12-31 | $286.83 Million | $-6.08 Million | -0.021x | +89.66% |
| 2019-12-31 | $89.87 Million | $-18.43 Million | -0.205x | -136.38% |
| 2018-12-31 | $-22.38 Million | $-12.62 Million | 0.564x | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more